| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 08/24/2005 | CN1658859A Therapeutic agent for overactive bladder |
| 08/24/2005 | CN1658857A NF-kB activation inhibitors |
| 08/24/2005 | CN1658855A O-substituted hydroxyaryl derivatives |
| 08/24/2005 | CN1658854A Immunity-related protein kinase inhibitors |
| 08/24/2005 | CN1658853A Monotherapy for the treatment of amyotrophic lateral sclerosis with cyclooxygenase-2 (COX 2) inhibitor(s) |
| 08/24/2005 | CN1658852A Amidine derivatives for treating amyloidosis |
| 08/24/2005 | CN1658848A Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds |
| 08/24/2005 | CN1658847A Use of EP4 receptor ligands in the treatment of IL-6 involved diseases |
| 08/24/2005 | CN1658837A Dry powder inhalant composition |
| 08/24/2005 | CN1658834A Method of treating mucus hypersecretion |
| 08/24/2005 | CN1658828A Gallocatechin gallate-containing composition |
| 08/24/2005 | CN1658767A Composition for modulating a physiological reaction or inducing an immune response |
| 08/24/2005 | CN1657534A Penthorum seponin (PCPTS) and its antihepatitis and antimutation aetion |
| 08/24/2005 | CN1657058A Health-care food |
| 08/24/2005 | CN1657056A Preparation and use of vasodilation liquid |
| 08/24/2005 | CN1216052C Anti-neurodegeneratively active 10-aminoaliphatyl-dibenz (b,f) oxepines |
| 08/24/2005 | CN1216047C Tricyclic lactam and sultam derivatives and their use as histone deacetylase inhibitors |
| 08/24/2005 | CN1216038C Novel dicarboxylic acid derivatives |
| 08/24/2005 | CN1215861C Xiasangju effervescent tablet and its preparing process |
| 08/24/2005 | CN1215828C Synergistic antiplaque/antigivitis oral composition |
| 08/23/2005 | US6934639 Using the three-dimensional structure of human collagenase-3 (MMP-13), a member of the matrix metalloproteinase (MMP) for drug design of MMP-13 inhibitors |
| 08/23/2005 | US6933373 Tumor suppressor protein for as a antiproliferative agent |
| 08/23/2005 | US6933321 For therapy of androgen-dependent diseases such as prostate cancer, benign prostatic hyperplasia, precicious puberty, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia and premature male baldness |
| 08/23/2005 | US6933320 Combination comprising combretastatin and anticancer agents |
| 08/23/2005 | US6933314 Integrin receptor inhibitors |
| 08/23/2005 | US6933313 Carbazoles with hydroxyfunctional amide (hydroxamic or esters) are for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock |
| 08/23/2005 | US6933306 Anticancer agents; antiinflammatory agents; autoimmune disease |
| 08/23/2005 | US6933304 Antitumor agents, osteoporosis |
| 08/23/2005 | US6933303 Antidiabetic agents |
| 08/23/2005 | US6933290 2-{N-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl}-amino}-alkylboronic acid derivatives |
| 08/23/2005 | US6933282 increasing the effective amount of tyrosine hydroxylase (TH) in the central nervous systems (CNS) for the purpose of increasing TH-mediated dopamine production in the treatment of Parkinson's disease |
| 08/23/2005 | US6933278 Administering as hypotensive agents, somatotrophins and optionally angiotensin 1-converting enzyme inhibitors, to humans having congenital disorders |
| 08/23/2005 | US6933142 Mammalian glycosylsulfotransferases expressed in high endothelial cells (HEC-GLCNAC6ST) and polypeptides coded by nucleic acids, used for medical diagnosis, drug screening and therapy |
| 08/23/2005 | US6932990 Comprises solvent extract of compressed cake derived from defatted evening primrose seed wherein effective component contains polyphenol-essential elements such as ellagic acid, gallic acid, pentagalloylglucose and catechin |
| 08/23/2005 | US6932984 Method of microencapsulation |
| 08/23/2005 | US6932973 Peptides which stimulate the expression of the cytokines of inflammation and promote tissue regeneration |
| 08/23/2005 | US6932960 Complexes with radionuclides; for use as contrast agent in magnetic resonance imaging (MRI); as parasiticide, viricide, or as chelation therapy of iron overload such as thalassemia; optimal combination of lipophilicity and hydrophilicity |
| 08/23/2005 | CA2469592C Hiv integrase inhibitors |
| 08/23/2005 | CA2370888C Renin inhibitors |
| 08/23/2005 | CA2310585C Novel administration form comprising an acid-labile active compound |
| 08/23/2005 | CA2267661C Variants of vascular endothelial cell growth factor having antagonistic properties |
| 08/23/2005 | CA2223469C Use of dopamine receptor antagonists in palliative tumour therapy |
| 08/23/2005 | CA2153235C Compounds having selectivity for retinoid x receptors |
| 08/23/2005 | CA2147341C Skin treatment composition comprising l-lactic acid and n-acetyl-l-cysteine |
| 08/23/2005 | CA2119782C Carbamate analogs of thiaphysovenine, pharmaceutical compositions, and method for inhibiting cholinesterases |
| 08/23/2005 | CA2111571C Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
| 08/23/2005 | CA2094276C Antibodies against the urokinase receptor and their use |
| 08/18/2005 | WO2005075421A1 Bicycloester derivative |
| 08/18/2005 | WO2005075414A1 Peptidyl arginine deiminase type iv inhibitor |
| 08/18/2005 | WO2005074988A1 Nerve cell differentiation inducer |
| 08/18/2005 | WO2005074911A1 Protein kinase c activator |
| 08/18/2005 | WO2005074909A1 Combination drug |
| 08/18/2005 | WO2005074907A1 Gene expression controlling agent |
| 08/18/2005 | WO2003004608A3 Drug metabolizing enzymes |
| 08/18/2005 | WO2002099049A3 Tbc1d1s as modifiers of the p53 pathway and methods of use |
| 08/18/2005 | US20050183146 Inhibitors of the inositol polyphosphate 5-phosphatase SHIP2 molecule |
| 08/18/2005 | US20050182418 Devices and methods for the restoration of a spinal disc |
| 08/18/2005 | US20050182256 1-{1-[4-(6-hydroxy-5-isobutyl-3-phenylpyrazin-2-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; antiproliferative |
| 08/18/2005 | US20050182126 2-Thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof |
| 08/18/2005 | US20050182112 3-[4-(3,6-dihydro-2H-thiopyran-4-yl) phenyl]-]5[1H or 2H-1,2,3-triazol-1 or 2-yl] oxazolidin-2-ones; grampositive bactericides for drug resistant bacteria, especially Staphylococcus, Enterococcus, and Streptococcus |
| 08/18/2005 | US20050182103 Substituted 2,3-diphenyl pyridines |
| 08/18/2005 | US20050182101 Prodrugs of proton pump inhibitors |
| 08/18/2005 | US20050182094 N-[[4-(2-Chloro-4-fluorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl benzenesulfonamide, used for prophylaxis of respiratory system disorders or as antiallergens |
| 08/18/2005 | US20050182093 Novel compounds |
| 08/18/2005 | US20050182077 8-amino-7-substituted-2,6-dioxo-1,2,3,6-tetrahydro-7H-purines; erectile dysfunction; sexual disorders; psychological disorders; hypotensive agents; restenosis; cardiovascular disorders; antidiabetic agents; vision defects; autoimmune diseases; anticancer agents |
| 08/18/2005 | US20050182070 Method for the treatment of allergic conditions |
| 08/18/2005 | US20050182069 For treatment of asthma, allergies, inflammation and anxiety; antihistamines; sedatives; tranquilizing agents; 2[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetamide |
| 08/18/2005 | US20050182068 Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues |
| 08/18/2005 | US20050182064 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
| 08/18/2005 | US20050182057 Aryl N-cyanoguanidines and methods related thereto |
| 08/18/2005 | US20050182054 Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
| 08/18/2005 | US20050182050 Therapeutic heterocyclic compounds |
| 08/18/2005 | US20050182045 Fused ring 4-oxopyrimidine derivative |
| 08/18/2005 | US20050182044 donepezil, rivastigmine, metrifonate, physostigmine, eptastigmine, galantamine, and huperzine A with beta-amyloid peptide inhibitor phenserine, tolserine, N1-benzylnorphysostigmine, N1-benzylnorphenserine, N1benzylnortolserine, N1-benzylnorcymserine, Alzheimer's disease |
| 08/18/2005 | US20050182040 Benzamide derivatives |
| 08/18/2005 | US20050182019 Phosphonate compounds |
| 08/18/2005 | US20050182017 Immunostimulatory nucleic acid molecules |
| 08/18/2005 | US20050182003 Drugs to be used in gene therapy for recessively transmitted genetic disease |
| 08/18/2005 | US20050181999 Comprising a biologically active agent (e.g., antifungal) , urea and an acid (lactic acid) or ethoxydiglycol; provide better bioavailability of the active agent within the nail |
| 08/18/2005 | US20050181996 Stimulation of cartilage growth with agonists of the non-proteolytically activated thrombin receptor |
| 08/18/2005 | US20050181980 Administering a formulation comprising an effective amount of:a sulfonylurea receptor 1 (SUR1) antagonist that reduces the activity of a NCCa-ATP channel; a pharmaceutically acceptable carrier |
| 08/18/2005 | US20050181971 Treatment of type i diabetes mellitus |
| 08/18/2005 | US20050181504 Using plug flow bioreactor system which mimics bone marrow microenvironment for propagation and maintenance of stromal cells |
| 08/18/2005 | US20050181462 Mutant androgen receptor, cancer cells expressing the same, a method of producing them and use thereof |
| 08/18/2005 | US20050181457 Mixture comprising immunogllobulin G complex for diagnosis, prevention and treatment of autoimmune and allergic disorders |
| 08/18/2005 | US20050181414 Peptides associated with serine protease active site for use in identification of modulators for treatment of cell proliferative disorders |
| 08/18/2005 | US20050181368 Protein for use in hypoxia related conditions |
| 08/18/2005 | US20050181066 Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency |
| 08/18/2005 | US20050181046 Tamper-resistant oral opioid agonist formulations |
| 08/18/2005 | US20050181038 Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system |
| 08/18/2005 | US20050180973 TREM-1 splice variant for use in modifying immune responses |
| 08/18/2005 | US20050180971 Cancer therapy |
| 08/18/2005 | US20050180961 Probiotics and oral tolerance |
| 08/18/2005 | US20050180959 Kinases involved in the regulation of energy homeostasis |
| 08/18/2005 | US20050180958 Using plug flow bioreactor system which mimics bone marrow microenvironment for propagation and maintenance of stromal cells; transplanting undifferentiated hemopoietic stem cells into a recipient |
| 08/18/2005 | DE10134196B4 Pharmazeutische Zusammensetzung zur Hemmung der unkontrollierten Vermehrung und/oder Induzierung der Apoptose von Zellen A pharmaceutical composition for inhibiting uncontrolled proliferation and / or inducing apoptosis of cells |
| 08/18/2005 | DE10008159B4 Verwendung von 2-Methyl-thiazolidin-2,4-dicarbonsäure und/oder ihrer physiologisch verträglichen Salze als Antikrebsmittel Use of 2-methyl-thiazolidine-2,4-dicarboxylic acid and / or their physiologically acceptable salts as an anti-cancer agent |
| 08/18/2005 | CA2555316A1 Combined pharmaceutical composition |
| 08/18/2005 | CA2555199A1 Peptidylarginine deiminase 4 inhibitor |
| 08/18/2005 | CA2555025A1 Use of factor viia factor for treating trauma |